April 27, 2026 - ROTOP Pharmaka GmbH today announced that it has received the building permit for a new radiopharmaceutical manufacturing facility in Dresden. The approval represents a major step in the company’s growth strategy and further strengthens its position as a leading radiopharmaceutical partner in Europe.
March 13, 2026 - We’re pleased to Welcome Dr. Michael Peterseim as our new Chief Financial Officer (CFO) at ROTOP. Dr. Peterseim brings many years of experience in financial leadership and has successfully guided companies through transformation processes, strengthened performance, and executed strategic transactions, particularly in growth situations.
I am a trained chemical-technical assistant (CTA). ROTOP offered me a role that included not only laboratory work but also regulatory affairs activities. This immediately caught my interest, as I had no prior experience in pharmaceutical regulatory affairs and there is no specific textbook-based training for this field. As a result, it was very
Every year brings new challenges due to changing regulations and requirements from legislators and the UN. I find this variety very motivating – there is no monotonous work here. In addition to my regular accounting tasks, I can also contribute to projects. My responsibilities are wide-ranging. During my time at ROTOP, I have developed
I actually came across the job posting quite by chance – and now I’ve celebrated my 5-year anniversary with ROTOP! I was particularly interested in the radiation protection aspect, having already completed a related course during my studies. I was therefore glad that my application was welcomed here and that the interview process was
August 15, 2025 - We are delighted to be featured in the latest issue of VentureCapital Magazine, which spotlights the Dresden region as a high-performance hub for key players and innovators in radiopharmaceutical innovation. ROTOP Pharmaka is recognized as a leading manufacturer of radiopharmaceuticals, including an iodine-123 compound used in Parkinson’s diagnostics. The article also emphasizes the strong network we are part of – combining research collaborations, advanced manufacturing, and the development of innovative theranostic solutions.
August 14, 2025 - We are delighted to announce that RoTecPSMA® has received marketing authorization in Switzerland, marking another important milestone in the European rollout of this innovative diagnostic solution. This approval, achieved in close collaboration with our trusted partner and marketing authorization holder medeo AG, paves the way for Swiss patients to benefit from our PSMA SPECT tracer.
July 18. 2025 - Team ROTOP - Jens Junker, Felix Roschke, Thomas Gottlieb and Tanmaya Joshi - just returned from SNMMI 2025 in New Orleans. This year, the event brought together nearly 8,000 professionals from across the nuclear medicine and radiopharmaceutical world.
May 14, 2025 - We are thrilled to announce that RoTecPSMA® has been approved in the United Kingdom! RoTecPSMA® is a technetium-99m cold kit for SPECT imaging of prostate cancer patients and the first PSMA-SPECT tracer approved in a European country. It marks a significant step forward in closing a gap in patient care, making advanced diagnostics more accessible for those affected by prostate cancer.
January 20, 2025 - ROTOP Pharmaka GmbH is pleased to announce new investments secured from GENUI & SHS Capital along with the appointment of Andrew Varghese as its new President of ROTOP USA. With the new investments ROTOP secured from GENUI & SHS Capital, ROTOP is further positioned to expand the footprint and be a significant player in the CDMO space to provide clinical and commercial batch volumes both in cold and hot products.
Contact
ROTOP Pharmaka GmbH
Bautzner Landstraße 400
01328 Dresden
GERMANY
Phone: +49 (0) 351 26 310 100
Email: info@rotop-pharmaka.de
Social Media
